Myovant Sciences to Present at Upcoming March Investor Conferences
- Cowen 40th Annual
Health Care Conferencein Boston, Massachusettson Wednesday, March 4, 2020at 9:20 a.m. Eastern time.
Barclays Global Healthcare Conferencein Miami, Floridaon Wednesday, March 11, 2020at 10:15 a.m. Eastern time.
A live webcast of the presentations will be accessible on the Events page under the Investors & Media section of the
About Myovant Sciences
Myovant Sciences aspires to be the leading healthcare company focused on innovative treatments for women’s health and prostate cancer. The company’s lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. The company has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
President, Chief Financial Officer
Director, Corporate Communications
Source: Myovant Sciences, Inc.